As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Evofem Biosciences, Inc. The largest reported stake is HUB Cyber Security Ltd.'s, at 9.99%. One filing is on record since August 4, 2026 (Schedule 13D, August 4, 2026).
Sell to companies like Evofem Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: HUB Cyber Security Ltd. · Sole voting: 14,709,204 · Shared voting: 0 · Sole dispositive: 14,709,204 · Shared dispositive: 0 · SCHEDULE 13D, 2026-08-04
- · Holder: HUB Cyber Security Ltd. · Percent: 9.99% · SCHEDULE 13D
- · Holder: HUB Cyber Security Ltd. · Percent: 9.99% · Shares: 14,709,204 · SCHEDULE 13D
Evofem Biosciences, Inc. has 1 Schedule 13D or 13G filing on record since 2026-08-04. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| HUB Cyber Security Ltd. | 9.99% | 14,709,204 | SCHEDULE 13D, 2026-08-04 | 2026-06-30 |
Holding shares or following this stake? See who's behind Evofem Biosciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Evofem Biosciences, Inc. and the records around it.
Evofem Biosciences, Inc. elsewhere on the record
- Form D filing Jul 2025
- Form D filing Apr 2025
Watch Evofem Biosciences, Inc.
Get an email when Evofem Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Evofem Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Evofem Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evofem Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| HUB Cyber Security Ltd. | 14,709,204 | 0 | 14,709,204 | 0 | SCHEDULE 13D, 2026-08-04 |
The latest filing identifies Evofem Biosciences, Inc. by CUSIP 30048L302 and gives its principal executive office as 7770 Regents Road, Suite 113-618, San Diego, CA 92122 (SCHEDULE 13D, 2026-08-04).
Source of funds (Item 3)
On June 26, 2026, HUB entered into securities purchase agreements (each, a "June Purchase Agreement" and, collectively, the "June Purchase Agreements"; the form of which is filed as Exhibit 99.1 hereto and incorporated herein by reference) with certain holders (each, a "June Seller" and, collectively, the "June Sellers") of senior subordinated convertible notes of the Issuer (the "Evofem Notes") and of certain purchase rights to acquire securities of the Issuer (the "June Purchase Rights").HUB Cyber Security Ltd., SCHEDULE 13D, 2026-08-04
Purpose of Transaction (Item 4)
HUB Cyber Security Ltd.
HUB acquired the Evofem Notes and the Purchase Rights for strategic investment purposes, as part of a broader transformation plan intended to strengthen HUB's financial position and expand into the women's health and wellness sector while preserving cash. HUB intends to explore opportunities to collaborate with the Issuer. On July 8, 2026, the Issuer issued to HUB a subordinated promissory note in the principal amount of $706,304 (the "Promissory Note"; filed as Exhibit 99.5 hereto and incorporated herein by reference), the proceeds of which are to be used by the Issuer exclusively for payments to its suppliers in connection with the purchase, manufacture, production and distribution of the Issuer's products, PHEXX and SOLOSEC. The Promissory Note is described in Item 6 and contains, among other things, covenants restricting certain actions of the Issuer without the consent of HUB, including mergers or consolidations, sales of all or substantially all assets, dissolution or bankruptcy filings, amendments to organizational documents and material changes to the nature of the Issuer's business. Subject to the Beneficial Ownership Limitations described in Item 5, the availability of authorized but unissued Common Stock of the Issuer and market and other conditions, HUB may from time to time convert all or a portion of the Evofem Notes, exercise all or a portion of the Purchase Rights, acquire additional securities of the Issuer, or sell, transfer or otherwise dispose of some …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-04; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-08-04 | HUB Cyber Security Ltd. | 9.99% | SCHEDULE 13D |
Also on the record for Evofem Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 2, 2025 | Form D, private offering | $925K sold | Form D page | Source |
| April 15, 2025 | Form D, private offering | $750K sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Evofem Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.